3 results about "Non small cell" patented technology

NOxPorfin is an on-demand porphyrin-based photosensitizer, described herein, designed to treat cancer via photodynamic therapy (PDT). A distinct advantage over existing FDA-approved photosensitizers is that NOxPorfin exhibits a suppressed singlet oxygen quantum yield (φΔ = 6%) prior to activation within cancer cells. This property translates to a severely compromised ability to harm healthy tissue. However, in the presence of nitric oxide, a common feature of all tumors, photosensitization increases by 650% (φΔ=45%). In addition, this is accompanied by a 70-fold fluorescence signal enhancement, which we designed to confirm NOxPorfin activation via clinical fluorescence imaging. The efficacy of NOxPorfin was successfully demonstrated in two murine models of cancer. First, we were able to selectively ablate aggressive breast cancer cells without causing collateral damage. Second, we were able to prevent the growth of nascent, non-small cell lung tumors. The latter study has implications in treating metastatic lesions.

The application discloses application of Hsap_1847317_1SS12GA_R+1 in preparation of a product for detecting tumor immunotherapy drug resistance, the immunotherapy is an immune checkpoint inhibitor treatment, and a nucleotide sequence of the Hsap_1847317_1SS12GA_R+1 is shown as SEQ ID NO. 1. In the technical scheme provided by the application, through a three-stage research process of screening-training-verification, it is found for the first time that Hsap_1847317_1SS12GA_R+1 is closely related to non-small cell lung cancer immunotherapy drug resistance, and it is confirmed that the Hsap_1847317_1SS12GA_R+1 can be used as an efficient detection marker. Research results show that in blood of patients after immunotherapy drug resistance, the expression amount of the Hsap_1847317_1SS12GA_R+1 is significantly up-regulated by about 10 times (P<0.0001), and excellent statistical significance is shown.